As Cartesian’s founders, we are physicians who have dedicated our careers to treating patients and curing diseases. We founded Cartesian because our own family members were diagnosed with cancer and we wanted to do something about it. We realized that curative therapies were not yet available, so we decided to develop them. In order to have curative potential, we recognized that therapies had to be potent yet safer. We also recognized that we could use cells to deliver these therapies directly to the site of disease. We focused on engineering cells with mRNA to accomplish these goals, and over time developed our platform technology, RNA Armory℠, to mRNA engineer any cell, to target to any tissue, any combination of therapies.
Today, we are treating patients in and beyond oncology as part of FDA-allowed clinical trials. We are grateful to our trial patients for partnering with us to bring cutting-edge therapies to patients with respiratory, autoimmune, and oncologic disorders.